SHOWNOTES
In this episode of Telltales, Mike, Jason, and Hunt walk through the latest Cash Flow Memo, from global oil and gas balances and U.S. deficits to Big Tech’s AI platform war and key healthcare and biotech updates. It’s a tour of where cash is really being earned today in energy, technology, and healthcare.
[00:00] Welcome, disclaimer & how to use the Cash Flow Memo
Mike kicks things off with the Telltales framework, a reminder to download the memo at telltales.us, and the usual “do your own work” investing disclaimer.
[00:31] Exhibit C: Oil, OPEC+ and a long stretch of $60 crude
Hunt walks through global oil supply and demand, highlighting Russian declines, Saudi increases, and flat demand in mature economies and China that could keep oil around $60 (or below) for 24–30 months before the market rebalances.
[06:03] Exhibit B: Natural gas supply wave, LNG buildout & data centers
They dissect the relentless growth in U.S. gas supply—especially associated gas from the Permian—volatile Henry Hub pricing, and how LNG exports and power demand (including AI data centers) are key to absorbing the glut.
[10:50] Exhibit A: U.S. deficits, healthcare subsidies & rising interest costs
Hunt reviews the federal budget picture, the fight over extending ACA tax credits, Medicare and Medicaid pressures, and why falling Fed funds rates may not translate cleanly into lower 10-year yields and mortgage rates.
[13:26] The platform war Apple lost to NVIDIA
Mike and Jason tell the story of CUDA vs OpenCL, how NVIDIA turned GPUs into a proprietary compute platform, why Apple retreated into Metal and Apple Silicon, and how that history explains today’s Gemini-powered Siri and Apple’s “rent the brain, own the user context” strategy.
[23:42] Big Tech scoreboard & AI market leadership
The team compares market caps of NVIDIA, Apple, Alphabet, and Microsoft, discusses “Mag 6” dynamics (minus Tesla), and weighs how much of Big Tech’s strength is justified cash flow versus AI-driven froth.
[25:36] Vertex: non-opioid pain strategy and next-gen channel targeting (memo p.15)
Jason updates Vertex’s non-opioid pain franchise, steady prescription growth, and early optimism around a new binding site targeting another pain channel as programs transition into human testing.
[26:16] Eli Lilly drops CVS Caremark for a smaller PBM (memo p.19)
They cover Lilly’s switch from CVS Caremark to Rightway, how conflicts of interest at large insurer-owned PBMs distort drug pricing, and why a more neutral model could better align incentives.
[26:44] CMS moves to close outpatient billing loopholes
Jason explains CMS’s push toward site-neutral payments for drug administration, especially chemo given in outpatient centers billed at hospital rates, and what that could mean for cancer care costs and Medicare spending.
[27:42] mRNA cancer vaccines: Moderna vs BioNTech’s cash flow choices (memo p.15)
Hunt, Jason, and Mike frame “cancer vaccines” as personalized post-treatment immunization, then contrast BioNTech’s cash-rich, capital-disciplined position with Moderna’s heavier post-COVID burn and what that implies for long-term investors.
Thanks for listening to Telltales. If this episode helped you think differently about cash flows and moats in energy, tech, and healthcare, hit subscribe, leave a review, and grab the full Cash Flow Memo at telltales.us.
This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.
